Sage Therapeutics(SAGE) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Sage Therapeutics Announces Second Quarter 2025 Financial Results Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 CAMBRIDGE, Mass. – July 30, 2025 – Sage Thera ...